FIA
DYN icon

FNY Investment Advisers’s Dyne Therapeutics DYN Stock Holding History

FNY Investment Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,500
Closed -$116K – 830
2021
Q1 		$116K Buy
+7,500
New +$145K 0.04% 287

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

FNY Investment Advisers's DYN Position: Q2 2021 in Review

FNY Investment Advisers sold out of Dyne Therapeutics (DYN) in Q2 2021, closing a stake of 7,500 shares — an estimated $116K sold.

FNY Investment Advisers first reported a position in DYN in Q1 2021 and held it in 1 quarter. The position peaked at $116K in Q1 2021. 76 funds tracked by Wall St. Rank hold DYN as of Q2 2021.

  • FNY Investment Advisers reported no remaining Dyne Therapeutics position as of Q2 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 7,500 Dyne Therapeutics shares in Q2 2021, an estimated $116K.
  • FNY Investment Advisers first reported a position in Dyne Therapeutics in Q1 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Dyne Therapeutics position peaked at $116K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2021.

Based on FNY Investment Advisers's 13F filing for Q2 2021, filed 14 Jul 2021.